Christopher Raymond
Stock Analyst at Raymond James
(2.71)
# 1,855
Out of 5,182 analysts
140
Total ratings
53.04%
Success rate
2.03%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Strong Buy | $46 | $24.75 | +85.86% | 1 | Mar 11, 2026 | |
| CLYM Climb Bio | Initiates: Strong Buy | $25 | $9.50 | +163.16% | 1 | Mar 11, 2026 | |
| COGT Cogent Biosciences | Maintains: Overweight | $39 → $52 | $36.61 | +42.06% | 2 | Feb 18, 2026 | |
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $5.99 | +167.11% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $5.63 | +344.44% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $6.46 | +101.24% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $9.13 | +217.63% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $111.90 | -37.44% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $180.67 | -36.35% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.59 | +466.04% | 6 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $126 | $53.81 | +134.18% | 15 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $4 | $5.47 | -26.87% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $227 | $197.38 | +15.01% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $426.01 | +25.11% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $744.44 | +36.08% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $23.99 | +483.58% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $54.02 | +33.28% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $4.41 | +194.78% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $8.66 | +766.05% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $9.59 | +692.49% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $36.92 | -10.62% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.42 | +181.69% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $340.18 | -15.34% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $24.43 | +67.83% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $35.93 | -22.07% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $104.04 | -61.55% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $7.50 | +1,100.00% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.17 | +8,105.13% | 2 | Mar 13, 2020 |
Alumis
Mar 11, 2026
Initiates: Strong Buy
Price Target: $46
Current: $24.75
Upside: +85.86%
Climb Bio
Mar 11, 2026
Initiates: Strong Buy
Price Target: $25
Current: $9.50
Upside: +163.16%
Cogent Biosciences
Feb 18, 2026
Maintains: Overweight
Price Target: $39 → $52
Current: $36.61
Upside: +42.06%
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $5.99
Upside: +167.11%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $5.63
Upside: +344.44%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $6.46
Upside: +101.24%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $9.13
Upside: +217.63%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $111.90
Upside: -37.44%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $180.67
Upside: -36.35%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.59
Upside: +466.04%
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $53.81
Upside: +134.18%
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $5.47
Upside: -26.87%
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $197.38
Upside: +15.01%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $426.01
Upside: +25.11%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $744.44
Upside: +36.08%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $23.99
Upside: +483.58%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $54.02
Upside: +33.28%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $4.41
Upside: +194.78%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $8.66
Upside: +766.05%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $9.59
Upside: +692.49%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $36.92
Upside: -10.62%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.42
Upside: +181.69%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $340.18
Upside: -15.34%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $24.43
Upside: +67.83%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $35.93
Upside: -22.07%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $104.04
Upside: -61.55%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $7.50
Upside: +1,100.00%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.17
Upside: +8,105.13%